文献速递青光眼

成人难治性青光眼Aurolab房水引流植入术后高眼压期的发生率与结局

Incidence and Outcomes of Hypertensive Phase Following Aurolab Aqueous Drainage Implant Surgery in Adults with Refractory Glaucoma.
PubMed 文献 · Am J Ophthalmol · 2020-08-21

本回顾性病例系列纳入200只接受Aurolab房水引流植入术且随访至少2年的成人难治性青光眼患眼,分析术后6周眼压≤21 mmHg者的资料。高眼压期定义为释放管结扎缝线后3个月内眼压>21 mmHg且无管阻塞,发生率为32%,多数经追加降眼压药物在3个月内缓解,且未显著影响长期成功率。

要点

  • AADI术后高眼压期发生率为32%,峰值眼压29.6±7.8 mmHg,多发于术后2-3个月。
  • 94%的高眼压期患眼经追加降眼压药物在3个月内缓解。
  • 高眼压期组与无高眼压期组累积成功率分别为71.8%与76.4%,差异无统计学意义(P=.23)。

核心结论

  • 约三分之一接受AADI的成人难治性青光眼患眼出现高眼压期。
  • 高眼压期多数可通过追加降眼压药物控制,且未显著影响长期成功率。

研究设计与样本

  • 回顾性、非对照、干预性病例系列。
  • 纳入所有接受AADI且随访至少2年的患眼,取术后6周眼压≤21 mmHg者进行统计分析,共200只眼。

主要发现

  • 64只眼(32%)发生高眼压期,峰值眼压为29.6±7.8 mmHg,峰值发生率在术后2-3个月。
  • 64只眼中60只(94%)在发病3个月内经追加降眼压药物缓解。
  • 高眼压期眼与无高眼压期眼的累积成功率分别为71.8%(95%CI=59.3%-81.2%)和76.4%(95%CI=68.7%-82.7%),P=.23。
  • 未调整Cox比例风险分析显示高眼压期眼失败风险 marginally 较高(HR=1.16,95%CI=0.6-2.1),但无统计学显著性(P=.61)。

关键数值与推荐

  • 高眼压期定义为释放管结扎缝线后3个月内眼压>21 mmHg(伴或不伴用药)且无管阻塞。
  • 统计分析对象为术后6周眼压≤21 mmHg的患眼。

临床怎么用

  • AADI术后3个月内应监测眼压,警惕高眼压期。
  • 发生高眼压期时优先追加降眼压药物,多数可缓解。
  • 高眼压期未必预示长期失败,仍需长期随访。

局限性

  • 回顾性、非对照设计。
  • 仅纳入随访至少2年且术后6周眼压≤21 mmHg的患眼,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the incidence and outcomes of hypertensive phase (HP) following Aurolab Aqueous Drainage Implant (AADI) (Aurolab) surgery in adults with refractory glaucoma. DESIGN: Retrospective, noncomparative, interventional case series. METHODS: All eyes that received the AADI and had a minimum of 2-year follow-up were identified, and data of patients who had intraocular pressure (IOP) ≤21 mm Hg at 6 weeks (ie, the time at which the tube-ligature suture dissolves) were used for statistical analysis. HP was defined as IOP >21 mm Hg during the first 3 months after the release of the tube ligating suture (with or without medications) in the absence of tube obstruction. RESULTS: A total of 200 eyes were included in the study, and HP was seen in 64 eyes (32%) with a peak IOP (mean ± SD) of 29.6 ± 7.8 mm Hg and peak incidence at 2-3 months after surgery. HP resolved within 3 months of its onset in 60 of the 64 eyes (94%) with additional IOP-lowering medications. The cumulative success rates were 71.8% (95% CI = 59.3%-81.2%) in HP eyes and 76.4% (95% CI = 68.7%-82.7%) in non-HP eyes (P = .23). Unadjusted Cox proportional hazards analysis showed that eyes experiencing HP had a marginally higher risk of failure (HR = 1.16, 95% CI = 0.6-2.1), but this relationship was not statistically significant (P = .61). CONCLUSIONS: A third of eyes that underwent AADI placement experienced HP. HP was successfully managed with additional IOP-lowering medications in a majority of cases and did not have a significant influence on long-term success rate.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Puthuran GV, Wijesinghe HK, Gedde SJ, et al. Incidence and Outcomes of Hypertensive Phase Following Aurolab Aqueous Drainage Implant Surgery in Adults with Refractory Glaucoma. Am J Ophthalmol. 2020. PMID: 32828879. doi:10.1016/j.ajo.2020.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。